Compare TCBIO & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B
Current Price
| Metric | TCBIO | CADL |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | 1818 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 339.8M |
| IPO Year | N/A | 2021 |
| Metric | TCBIO | CADL |
|---|---|---|
| Price | $20.67 | $6.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.43 |
| AVG Volume (30 Days) | N/A | ★ 1.0M |
| Earning Date | N/A | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $4.25 |
| 52 Week High | N/A | $13.68 |
| Indicator | TCBIO | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 62.01 |
| Support Level | $20.58 | $5.45 |
| Resistance Level | $20.97 | $6.14 |
| Average True Range (ATR) | 0.21 | 0.42 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 36.70 | 54.43 |
Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customised solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment, excluding mortgage finance loans and other national lines of business. Texas Capital has established commercial banking, consumer banking, investment banking and wealth management capabilities.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.